GV 101
Alternative Names: GV-101; OV-888Latest Information Update: 27 May 2025
At a glance
- Originator Graviton
- Developer Graviton; Ovid Therapeutics
- Class Antifibrotics; Small molecules
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cavernous haemangioma
- Clinical Phase Unknown CNS disorders
- Preclinical Hepatic fibrosis
Most Recent Events
- 20 May 2025 Graviton Bioscience Corporation plans a phase II trial for Obesity in July 2025 (PO, Suspension) (NCT06979505)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Cavernous-haemangioma(In volunteers) in USA (PO, Suspension)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Cavernous-haemangioma(In volunteers) in USA (PO, Tablet)